[The place of Glitazones in the treatment of diabetes: after the PROactive study].
Thiazolidinediones (TZD) have recently been introduced as an oral hypoglycaemic agent. A vast amount of data indicates that TZD also exhibit beneficial cardiovascular effects. This article reports on the results from the large PROactive study. After 3 years of pioglitazone treatment a reduction in the frequency of death, non-fatal myocardial infarction and cerebral infarction was demonstrated in type 2 diabetic subjects. However, there were side effects in terms of cardial insufficiency and edema. Though this study provides some clear cut answers, it also raises a lot of questions.
Schmitz
Ole E
OE
Arhus Universitetshospital, Medicinsk Endokrinologisk Afdeling M. ole.schmitz@ki.au.dk
Brock
Birgitte
B
Rungby
Jørgen
J
Madsbad
Sten
S
D002318:Cardiovascular Diseases / Q000517:prevention & control; D048909:Diabetes Complications / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D003925:Diabetic Angiopathies / Q000517:prevention & control; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D000077205:Pioglitazone; D011446:Prospective Studies; D012107:Research Design; D012307:Risk Factors; D045162:Thiazolidinediones / Q000008:administration & dosage*
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077205:Pioglitazone